News

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Eli Lilly and Company (NYSE:LLY) is included among the 10 Best US Stocks to Invest in According to Billionaires. Eli Lilly and Company (NYSE:LLY) discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. On May 8, Guggenheim analyst Seamus Fernandez boosted the firm’s price target on Eli Lilly […]

Eli Lilly (NYSE:LLY) announced a $50 million partnership with UNICEF USA tied to its 150th anniversary. The multi-year program targets childhood non-communicable diseases across 21 low and middle income countries. The company is also supporting large scale food distribution and infrastructure projects in the US. Eli Lilly is bringing its ESG profile into sharper focus with this UNICEF USA partnership, which centers on expanding primary care capacity for conditions like childhood diabetes...

By Daniella Parra Imviva Biotech said data showed its CTA313 drug resulted in 50% of patients going into remission for systemic lupus. Many patients experience incomplete responses, recurrent flares and long-term treatment-related toxicity, it said. “The clinical activity observed with CTA313 in systemic lupus erythematosus is highly encouraging, with 100% of patients achieving an SRI-4 […]

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Eli Lilly (NYSE:LLY) just delivered one of the most impressive quarters in big pharma history, and the stock is responding. After a sharp drawdown in early 2026, shares have rebounded 9.27% over the past month as Mounjaro and Zepbound continue to redefine the obesity and diabetes treatment landscape. Our 24/7 Wall St. price target points ... Is Eli Lilly Going To $1,100?

Eli Lilly and Company (NYSE:LLY) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. During the lightning round, a caller inquired about the stock, and Cramer replied: Eli Lilly, I did a tremendous amount of work on Eli Lilly. I was […]

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.

Pfizer stock slipped after Q1 results despite an earnings beat as investors weighed falling COVID sales and looming patent expirations.

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

Is LLY a good stock to buy? We came across a bullish thesis on Eli Lilly and Company on Value & Momentum Portfolio’s Substack. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $987.05 as of May 6th. LLY’s trailing and forward P/E were 35.13 and 28.82 […]

On Tuesday, William Blair initiated coverage on Kailera Therapeutics Inc. (NASDAQ:KLRA), the latest entrant in the fast-growing weight-loss drug market. The obesity-focused biotech raised more than $600 million in April through an initial public offering of 39.06 million shares priced at $16 each. Kailera Portfolio ‘Strongly Mirrors’ Eli Lilly William Blair analyst Andy Hsieh said Kailera’s obesity pipeline could position the company as a future challenger in the expanding weight-loss market, ci

LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.

Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients were able to maintain significant weight loss after switching from higher-dose injectable incretin therapies to either Foundayo or lower-dose Zepbound. • Eli Lilly stock is showing upward bias. What should traders watch with LLY? The company presented data from the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN studies at the 33rd European Congress on Obesity. The findings were also p

Micron Technology is on pace to close above the $900 billion market value for the first time, according to Dow Jones Market Data. The semiconductor company, whose stock is up 4.8% today, is on pace to become the 11th largest U.S. company by market cap.

ETFs like XLV stand out as aging U.S. demographics fuel rising demand for healthcare, medical devices and senior-focused care.

FEATURE Micron Technology stock was gaining early Wednesday. Labor unrest at Samsung Electronics could intensify the memory-chip supply crunch.  Micron shares were up 3.1% in early trading. Talks between Samsung and its labor union to avert a walkout collapsed on Wednesday.

If it feels like growth stocks can’t continue their outperformance much longer, ignore that feeling. The Vanguard S&P 500 Growth Index Fund Exchange-Traded Fund, home to companies with high sales growth including Nvidia Advanced Micro Devices Microsoft and Eli Lilly is up 13% in the past month. A couple of factors have driven the performance of the growth stocks.

Eli Lilly, Novo, JP Morgan, Coca-Cola, PepsiCO and Mondelez have been highlighted in this Investment Ideas article.

While the company has more publicly highlighted its AI developments in Europe, onboarding Vipin Gopal indicates its US division is ready to do more with this tech.

Eli Lilly (NYSE:LLY) reported new late phase clinical data on its obesity portfolio. Patients with obesity maintained significant long term weight loss after switching from injectable to oral therapies. The trials highlighted Foundayo and Zepbound as durable options for ongoing weight management and showed a consistent safety profile for the new oral GLP 1 therapy. Eli Lilly enters this update with its stock at $989.87 and 5 year share price gains of 432.2%. The company has also delivered a...

Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.

Few stocks have polarized investors in 2026 like Eli Lilly (NYSE:LLY). After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of fundamentals. Here is where I land on the $1,000 debate. The 24/7 Wall St. Price Target for Eli Lilly Eli Lilly trades at $948.45 as ... Eli Lilly Price Prediction: This Is Where The Stock Will End This Year

These growth stocks are benefiting from major tailwinds across cloud computing, digital payments, and healthcare.

Moby summary of Hims & Hers Health, Inc.'s Q1 2026 earnings call

A spike in facility sales to outsourcing companies points to an industry need for greater flexibility.

The market adage “Sell in May and Go Away” rarely fits a single name cleanly. Eli Lilly (NYSE: LLY) is an unusual exception this spring. The GLP-1 leader has ripped higher off its post-earnings lows yet remains underwater for the year, an asymmetric setup that draws seasonal traders toward a tactical trim. The Setup: A ... Lilly Bounces Into ‘Sell in May’ Territory as Pricing Pressures Loom

Eli Lilly's Omvoh (mirikizumab) has shown durable disease clearance over four years in patients with moderately to severely active ulcerative colitis. The long term data adds to existing evidence on Omvoh's efficacy and safety in inflammatory bowel disease. The results reinforce Eli Lilly's position in immunology and provide new information for clinicians and patients considering chronic treatment options. Eli Lilly (NYSE:LLY) enters this update with Omvoh's four year results adding another...